Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article (13)

Advertisement

Research Article Free access | 10.1172/JCI105822

ECHO-11 as a respiratory virus: quantitation of infection in man

Gilbert S. Saliba, Sylvia L. Franklin, and George Gee Jackson

Research and Educational Hospitals, Department of Medicine, University of Illinois College of Medicine, Chicago, Illinois 60680

Find articles by Saliba, G. in: JCI | PubMed | Google Scholar

Research and Educational Hospitals, Department of Medicine, University of Illinois College of Medicine, Chicago, Illinois 60680

Find articles by Franklin, S. in: JCI | PubMed | Google Scholar

Research and Educational Hospitals, Department of Medicine, University of Illinois College of Medicine, Chicago, Illinois 60680

Find articles by Jackson, G. in: JCI | PubMed | Google Scholar

Published June 1, 1968 - More info

Published in Volume 47, Issue 6 on June 1, 1968
J Clin Invest. 1968;47(6):1303–1313. https://doi.org/10.1172/JCI105822.
© 1968 The American Society for Clinical Investigation
Published June 1, 1968 - Version history
View PDF
Abstract

Through a series of controlled experiments in volunteers, quantitative aspects of infection, illness, and immunity to ECHO-11 virus were studied. ECHO-11 is a transmissable viral infection in man and equally infectious to the upper respiratory and the intestinal tracts. The rate of infection was directly related to the dose of virus exposure, but any infectious dose of virus produced illness in only about one-third of the infected subjects. The infectious dose for man varied over a billionfold range. Larger challenge doses caused no difference in the local symptoms at the portal of entry or in the peak severity of illness, but symptoms were more diverse and prolonged after a higher dose. Persons with asymptomatic infections became just as heavily infected as ill persons.

In respiratory secretions from natural infection, the titer of infectious virus was found to be about 102 median infective doses in tissue culture (TCID50)/ml. At this level, up to 40% of exposed contacts could be infected per milliliter of secretion. The observed rate of spread was 24%. This low-dose inoculum caused illness in 12% of volunteers but failed to elicit a significant antibody response in 93% or immunity to reinfection and another illness upon rechallenge. Larger doses of virus produced a longer excretion of virus and a significant increase in serum-neutralizing antibody. Nasal antibody was infrequently found. The principal effect of antibody was to decrease virus excretion and to shorten illness; it reduced the rate but did not prevent infection. Attempts to produce an asymptomatic enteric infection which would induce immunity failed.

The characteristics of respiratory transmission with mild disease, recurrent infection, and illness without a detectable antibody response or solid immunity to reinfection, satisfy the epidemiologic conditions to establish ECHO-11 virus as one of the causes of the common cold.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1303
page 1303
icon of scanned page 1304
page 1304
icon of scanned page 1305
page 1305
icon of scanned page 1306
page 1306
icon of scanned page 1307
page 1307
icon of scanned page 1308
page 1308
icon of scanned page 1309
page 1309
icon of scanned page 1310
page 1310
icon of scanned page 1311
page 1311
icon of scanned page 1312
page 1312
icon of scanned page 1313
page 1313
Version history
  • Version 1 (June 1, 1968): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article (13)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts